This page is an archive. Its content may no longer be accurate and was last updated on the original publication date. It is intended for reference and as a historical record only. For hep C questions, call Help4Hep BC at 1-888-411-7578.
George N. Ioannou, MD, associate professor, VA Puget Sound Health Care System, University of Washington School of Medicine, discusses a study evaluating the effectiveness of direct antiviral agents for hepatitis C virus patients with hepatocellular carcinoma (HCC).
The study aimed to understand the real-world effectiveness of antiviral agents sofosbuvir (SOF), ledipasvir/sofosbuvir (LDV/ SOF) and paritaprevir/ritonavir/ombitasvir and dasabuvir (PrOD) by hepatitis C genotype and clinically relevant subgroup.
These results were both encouraging and interesting, says Ioannou.